Details for Patent: 8,642,538
✉ Email this page to a colleague
Which drugs does patent 8,642,538 protect, and when does it expire?
Patent 8,642,538 protects VIEKIRA XR, TECHNIVIE, and VIEKIRA PAK (COPACKAGED), and is included in three NDAs.
This patent has one hundred and fourteen patent family members in forty-one countries.
Summary for Patent: 8,642,538
| Title: | Macrocyclic hepatitis C serine protease inhibitors |
| Abstract: | The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. |
| Inventor(s): | Ku; Yiyin (Buffalo Grove, IL), McDaniel; Keith F. (Wauconda, IL), Chen; Hui-Ju (Grayslake, IL), Shanley; Jason P. (Chicago, IL), Kempf; Dale J. (Libertyville, IL), Grampovnik; David J. (Waukegan, IL) |
| Assignee: | AbbVie, Inc. (North Chicago, IL) |
| Application Number: | 13/439,551 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,642,538
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HCV INFECTION USING PARITAPREVIR | ⤷ Sign Up | ||
| Abbvie | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HCV INFECTION USING PARITAPREVIR | ⤷ Sign Up | ||
| Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HCV INFECTION USING PARITAPREVIR | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,642,538
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2340029 | ⤷ Sign Up | CA 2015 00013 | Denmark | ⤷ Sign Up |
| European Patent Office | 2340029 | ⤷ Sign Up | PA2015011 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2340029 | ⤷ Sign Up | C20150019 00156 | Estonia | ⤷ Sign Up |
| European Patent Office | 2340029 | ⤷ Sign Up | 92667 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2340029 | ⤷ Sign Up | 1590012-9 | Sweden | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
